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  Objective(s): Valproic acid (VPA) has proven to be as one of the most promising useful drug with 
anticancer properties. In this study, we investigate the VPA effects on E-cadherin expression in 
HeLa, TC1, MKN45, and HCT116 cell lines.  This study assesses the effects of VPA on human 
papillomavirus E7 expression in HPV positive cell lines. 
Materials and Methods: Cell lines were treated by 2 mmol/l VPA and expression of E-cadherin and 
E7 was analyzed by quantitative real-time PCR. Student’s t test and ANOVA were used to 
determine changes in expression levels. 
Results: The results revealed that mean of E-cadherin expression is increased by VPA 1.8 times in 
HCT116 and MKN45 cell lines, also the mean of E-cadherin mRNA levels is up-regulated 2.9 times in 
HeLa and TC1 cell lines. So, E-cadherin augmentation induced by VPA in HeLa and TC-1, HPV 
positive cell lines, is higher than HPV negative cell lines MKN45 and HCT116. The mean of HPV E7 
expression is decreased by VPA, 4.6 times in in HeLa and TC-1 cell lines.   
Conclusion: This study demonstrates that re-expression of E-cadherin by VPA in HPV positive cell 
lines is more than HPV negative cell lines. Whereas, HPV E7 reduces the expression of E-cadherin, 
reduction of HPV E7 expression by VPA is related to more augmentation of E-cadherin in HPV 
positive cell lines. So, this study demonstrates that VPA has more anticancer properties in HPV 
positive cell lines, and could potentially be a promising candidate for cervical cancer treatment. 
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Introduction 
Cervical cancer is one of the most common 
cancers in women worldwide with more than 
200000 deaths, annually (1). Approximately 80% of 
them live in developing countries where this disease 
is detected at late stage; so, new treatment drugs for 
cervical cancer are needed (2, 3). 
Development of cervical cancer is caused by high-
risk human papillomaviruses (hrHPVs) (4). They are 
small, nonenveloped, and nonlytic viruses with 
dsDNA genome that are tropic for squamous 
epidermis. The cervical carcinogenesis is associated 
with E6 and E7 oncoproteins from hrHPVs (4). E6 
and E7 viral oncogenic proteins inactivate two 
cellular tumor suppressor proteins p53 and pRB, 
respectively (5, 6), and are necessary for cells 
proliferation and DNA damage that eventually lead 
to cancer (7). 
The development of cervical cancer related to 
changes in epigenetic patterns of cells such as                
DNA methylation, histone methylation, and histone  
acetylation (8). Histone acetylation is one of the most 
important epigenetic mechanisms that neutralizes 
the positive charge of histone proteins, unfolds the 
chromatin structure and associated DNA, and 
induces transcription and gene expression (9). 
The acetylation of histone proteins is regulated 
by histone acetyltransferase (HATs) and histone 
deacetylases (HDACs). HDACs remove the acetyl 
groups on the lysine residues of histones and induce 
positive charge on histone proteins, this leads to 
aberrant transcription and gene suppression. So, 
HDACs could reduce the expression of tumor 
suppressor genes to development of cancer (10). 
Histone deacetylase inhibitors (HDACIs) have 
appeared as the promising drugs for cancer (11, 12). 
HDACIs have been classified to 5 groups: 1. short 
chain fatty acids (e.g., butyrates and valproic acid), 2. 
organic hydroxamic acids (e.g., suberoylanilide 
bishydroxamine (SAHA) and trichostatin A (TSA), 3. 
sulfonamide anilides, 4. benzamides (e.g., MS-275), 5. 
cyclic tetrapeptides (13). 
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Among HDACIs, valproic acid (VPA) has been 
demonstrated as a drug with anticancer properties. 
VPA is used for treatment of cluster migraine, 
headaches, and epilepsy (14), but antineoplastic 
activity of VPA was shown in 1997 (15). VPA 
increases apoptosis and reduces angiogenic activity 
in various tumor cells (16). It also inhibits invasion 
and migration of tumor cells by several mechanisms 
(16-19). 
To start the process of invasion and metastasis, a 
malignant cell must first break away from the 
cancerous tumor. In cancer cells, the expression of 
adhesion molecules seems to be reduced. E-cadherin 
is one of the most important adhesion molecules 
encoded by CDH1 gene, and the dominant epithelial 
cell-adhesion molecule. This protein is expressed on 
basal and suprabasal cells and plays important role 
in epithelial structural integrity (20, 21). The 
suppression of E-cadherin expression has been 
widely reported in different epithelial tumors (22-
27). The loss of E-cadherin is associated with 
invasion and metastasis (28). 
In this work, we compare the effects of VPA on E-
cadherin expression in two groups of cell lines, HPV 
positive and HPV negative cell lines. Also, we study 
the effects of VPA on E7 oncoprotein expression in 
HPV positive cell lines. 
 
Materials and Methods 
Cell culture 
The HPV positive cell line; HeLa, a cervical 
carcinoma cell line that contains HPV18 DNA, and TC1 
which is transduced to express the E6 and E7 
oncogenes of HPV16, were grown in Dulbecco's 
modified Eagle's medium (DMEM) (Gibco). Growth 
media was supplemented with 10% heat inactivated 
fetal calf serum (Life Technologies, Camarillo,                   
CA, USA), 100 μg/ml penicillin/streptomycin 
(Invitrogen, Life Technologies, Camarillo, CA, USA), 
and 2 mM L-glutamine (Sigma-Aldrich, MO, USA). 
The HPV negative cell lines; HCT116 and MKN45, were 
also cultured in the same condition. All of the cell 
lines were maintained in humidified incubator with 
5% CO2. 
 
Valproic acid preparation  
Valproate sodium salt was prepared from sigma 
(Sigma-Aldrich, MO, USA) and was dissolved in 
phosphate buffered saline (PBS) to 1, 2, and 5 mM 
concentrations.  
 
Proliferation assay  
Cell proliferation was performed using the 3-(4, 
5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT) dye reduction assay. HeLa, TC1, 
HCT116, and MKN45 cell lines were seeded at a density 
of 5×104 per well in 96 well culture plates and 
incubated overnight with DMEM containing 10% 
fetal calf serum. After 24 hr, the cells were treated 
with medium containing VPA at concentrations of 0, 
1, 2, and 5 mmol/L, for three days. After 24, 48, and 
72 hr, MTT was added at concentration of 0/5 mg/ml 
for 4 hr. The absorbance was determined at 570 nm. 
 
RNA preparation 
The four cell lines (HCT116, MKN45, HeLa, and TC1) 
were cultured in 12 well culture plates to 80 percent 
confluency and were treated with medium 
containing 2 mmol/l VPA for 48 hr. According to 
experimental studies, our experiments were 
performed three times to achieve valid results; so, 
we did real-time PCR analysis for each experiment 
using 3 samples. The cells were harvested and 
resuspended in 250 μl volume of sterile PBS. Total 
RNA was extracted from cells using TriPure total 
RNA isolation Kit according to the manufacturer’s 
procedure (Roche Applied science, Indianapolis, IN, 
USA). Extracted RNA concentration and purity were 
analyzed at the wavelength of 260 nm by                
nanodrop spectrophotometry (Eppendrof, Humburg, 
Germany). RNA integrity was visually assessed with 
1% agarose gel electrophoresis. The RNA with 
absorption ratio OD 260 nm OD 280 nm between 1/8 
and 2 was used for cDNA synthesis. 
 
cDNA synthesis 
cDNA was prepared from total RNA by reverse 
transcription using M-MuLV reverse transcriptase 
(Fermentas, Vilnius, Lithuania), random hexamers, 
and RNase inhibitor (Vivantis). One μg of RNA was 
added by 2 μl of 10 mM dNTPs along with 1 μl of (0.2 
μg/μl) random hexamer, 1 μl (20 u/μl) of M-MuLV, 
and 0.5 μl of RNase inhibitor in a sterile 
microcentrifuge tube. The final volume was made up 
to 20 μl by adding sterile distilled water and was 
mixed well. These tubes were incubated at room 
temperature for 10 min and then were incubated at 
42 ℃ for one hr. The M-MuLV enzyme inactivation 
step was done by a step for 10 min at 70 ℃. The 
synthesized cDNA was diluted 10 times in sterile 
distilled water and was used as a template for 
quantitative real-time PCR analysis. 
 
Quantitative real-time PCR 
Expression of E-cadherin mRNA was analyzed by 
quantitative real-time PCR using the SYBR Premix               
Ex Taq II kit (TAKARA Bio INC., Otsu, Japan) on an  
Applied Biosystems® StepOnePlus™ Real-Time PCR 
system (Applied Biosystems, Foster city, CA, USA). 
Quantitative real-time PCR was performed using the 
following primer sequences: E-cadherin, forward:  
5′-AGGGGTTAAGCACAACAGCA-3′ and reverse: 5′-GG- 
TATTGGGGGCATCAGCAT-3′; HPV E7, forward:                   
5′-ATGCATGGAG ATACACCTAC-3′ and reverse:                       
5′-TTATGGTTTCTGAGAACAGATG-3′, and glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH), 
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forward: 5′-ATGTTCGTCATGGGTGTGAA-3′ and 
reverse: 5′- GGTGCTAAGCAGTTGGTGGT-3′. Briefly, 
10 μl SYBR Premix Ex Taq II (2x), 0.4 μl ROX 
Reference Dye (50x), and 0.8 μl of forward and 
reverse primers with 2 μl of 1/10 diluted cDNA were 
used in a total volume of 20 μl.  The temperature 
profile for all genes was 95 ℃ for 1 min; 40 cycles of 
95 ℃ for 15 sec, 55 ℃ for 30 sec, and 72 ℃ for 30 
sec; melting curve program (60-95 ℃). All samples 
were run in triplicate simultaneously with negative 
controls. The threshold cycle (ct) of E-cadherin 
mRNA level of VPA treated cell lines was compared 
with the threshold cycle generated by the control 
samples. E-cadherin mRNA levels were normalized 
to the expression of the endogenous housekeeping 
gene GAPDH by the 2 –ΔΔct method (29). 
 
Statistical analysis 
The unpaired, two-tailed student’s t was done to 
analyze the statistical differences between groups 
using Graph-Pad Prism software. mRNA levels 
comparisons between groups were analyzed using 
ANOVA test. A P-value less than 0.05 (P<0.05) was 
considered to be statistically significant for the 
differences and determined by asterisk in the 
corresponding figures. 
 
Results 
Optimization of the valproic acid concentration for 
E-cadherin expression  
The cell lines were treated by 1, 2, and 5 mM VPA 
and harvested 24, 48, and 72 hr after treatment. 
MMT assay and quantitative real-time PCR results 
for E-cadherin mRNA levels showed that 2 mM VPA 
after 48 hr gave the highest amount of E-cadherin 
expression (data not shown). 
 
Valproic acid up-regulated E-cadherin expression 
in HPV negative cell lines   
Two HPV positive cell lines, HCT116 and MKN45, 
were treated by 2 mM VPA to study the E-cadherin 
mRNA level changes. Cells were harvested 48 hr after 
treatment, total RNA was extracted, and cDNA was 
synthesized by 1 µg RNA. Then E-cadherin 
expression was analyzed by quantitative real-time 
PCR. Each experiment was done three times (n=3). 
The results revealed that E-cadherin expression is 
increased 1.7 and 2 times in HCT116 and MKN45 cell 
lines in comparison to control cells with P-value= 
0.0423 and P-value = 0.0042, respectively (Figure 
1A, B). 
 
E-cadherin expression is increased in HPV positive 
cell lines by valproic acid 
The two HPV positive cell lines, HeLa and TC1 
were treated by 2 mM VPA, and E-cadherin mRNA 
level was analyzed. Each experiment was done three 
times (n=3). The results showed that E-cadherin  
 
 
 
 
 
 
Figure 1. E-cadherin expression is increased in human 
papillomavirus negative cell lines by valproic acid. HCT116 and 
MKN45 cell lines were treated by 2 mM VPA when the cells reached 
80% confluency. After 48 hr of treatment, cells were harvested 
and fold change of E-cadherin expression was analyzed by real 
time PCR using the 2–ΔΔCt method. (A) E-cadherin mRNA level in 
HCT116 cells treated by VPA. (B) E-cadherin mRNA level in MKN45 
cells treated by VPA. Each experiment was done three times (n=3). 
* P< 0.05, ** P< 0.01 
 
 
mRNA level is significantly up-regulated, 3.2 and 2.6 
times in HeLa and TC1 cell lines with P-value = 
0.0028 and P-value = 0.0089, respectively (Figure 
2A, B). 
 
The E-cadherin augmentation is induced by 
valproic acid in HPV positive cell lines higher than 
HPV negative cell lines are 
The experiments showed that E-cadherin expression 
is increased by VPA in both in HPV positive and 
negative cell lines; whereas, E-cadherin 
augmentation in HeLa and TC1 (Mean=2.9), HPV 
positive cell lines, is higher than HPV negative cell 
lines, MKN45 and HCT116 (Mean=1.85)  (Figure 3). 
 
Valproic acid down-regulated HPV E7 expression 
in HeLa and TC1 cell lines  
Previous studies revealed the relationship 
between HPV E7 oncoprotein and E-cadherin 
expression. One study showed that expression of 
the HPV16 E7 reduces the expression of E-cadherin in 
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Figure 2. Valproic acid up-regulated E-cadherin expression in 
human papillomavirus positive cell lines. Hela and TC1 cell 
lines were cultured by DMEM containing 2 mM VPA. After 48 hr 
treatment, cells were harvested and fold change of E-cadherin 
expression was analyzed by real time PCR using the 2–ΔΔCt method.  
(A) E-cadherin mRNA level in Hela cell line treated by VPA. (B) E-
cadherin mRNA level in TC1 cell line treated by VPA. Each 
experiment was done three times (n=3). * P< 0.05, ** P< 0.01 
 
 
 
 
Figure 3. The E-cadherin augmentation induced by valproic acid 
in HPV positive cell lines is higher than HPV negative cell lines 
 
 
 
 
 
Figure 4. Valproic acid down-regulated HPV E7 expression in 
human papillomavirus positive cell lines. Hela and TC1 cell 
lines were treated by 2 mM VPA. After 48 hr of treatment, cells 
were harvested and fold change of HPV E7 expression was 
analyzed by real time PCR using the 2–ΔΔCt method. (A) HPV E7 
expression in Hela cell line treated by VPA. (B) HPV E7 expression 
level in TC1 cell line treated by VPA. Each experiment was done 
three times (n=3). Error bars represent SEM. * P< 0.05, ** P< 0.01 
 
MDCK cells, and Caberg et al demonstrated that 
suppression of HPV E7 using siRNA in HPV16 
transformed human keratinocytes, restores the E-
cadherin expression in these cells (30, 31). So, we set 
out to test the VPA effects on HPV E7 expression in 
HeLa and TC1 cell lines. Each experiment was done 
three times (n=3). The results showed that HPV E7 
expression is decreased 5.2 and 4 times in HeLa and 
TC1 cell lines with P-value= 0.0058 and P-value= 
0.0069, respectively  (Figure 4A, B). 
 
Discussion 
Epigenetic is composed inducible genetic changes 
that regulates gene expression. DNA methylation and 
histone acetylation are two most common mechanisms 
that induce epigenetic changes (32). DNA methylation 
occurs at cytosine within CpG islands and it is catalyzed 
by DNA methyltransferases (DNMTs) protein family 
(33). DNA methylation directly interferes with 
transcription factors binding to recognition regions in 
promoter sites, and causes transcriptional suppression 
(34). Interaction of DNMTs with other chromatin 
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modifying enzymes such as HDACs and histone 
methyltransferase brings these proteins in the vicinity 
of promoter sites and alters gene expression (35-38). 
Positive charge at lysine residues neutralized by 
histone acetylation, loosen the chromatin structure that 
finally causes transcriptionally active chromatin (9, 10). 
DNMTs bring HDACs in the vicinity of promoter 
regions, cause local histone deacetylation, and 
condense chromatin structure that reduce gene 
expression levels by limiting accessibility of 
transcription factors to this sites (39). HDACs include 
18 genes that are divided into 4 classes (13).  
HDACIs have emerged as the hopeful clinical drugs 
for cancer (11, 12). VPA has proven as one of the most 
encouraging useful therapeutics with anticancer 
properties. In comparison with other HDACIs such as 
trapoxin and trichostatin A that have toxic side effects, 
VPA is relatively nontoxic and safe in vivo (13). VPA 
inhibits invasion and migration of tumor cells by 
several mechanisms (16-19). 
During epithelial to mesenchymal transition 
(EMT) process, a malignant cell can break away from 
the cancerous tumor (40). A critical molecular 
feature of EMT is the downregulation of E-cadherin 
(41). E-cadherin acts as a tumor suppressor protein 
and inhibits invasion and metastasis. (42). 
EMT provides molecular mechanisms for cervical 
cancer metastasis, and decreased or aberrant 
expression of E-cadherin have been reported in 
cervical carcinoma (43-45).  
Carcinoma of the cervix is the second most 
common cancer in women worldwide (1). 
Development of this cancer is caused by the 
integration of hrHPVs in the host genome (4 HPV E6 
and E7 viral proteins may induce EMT in cervical 
cancer (46, 47), so in this study we analyzed valproic 
acid effects on E-cadherin expression in HPV positive 
cell lines and HPV negative cell lines. 
Our results showed that E-cadherin expression is 
increased in HPV positive cell lines (HeLa and TC1) 
and HPV negative cell lines (MKN45 and HCT116); this 
result is consistent with previous studies. The 
expression of E-cadherin is up-regulated by VPA in 
LNCaP, DU145, PC3, and luminescent PC3 prostate 
cancer cell lines and prostate cancer xenograft 
mouse models (48). The VPA effects on ovarian 
cancer using human ovarian cancer cell line SKOV3 
and a human ovarian cancer model transplanted 
subcutaneously in nude mice showed increased 
expression of E-cadherin and reduced matrix 
metalloproteinase-9 and VEGF in vitro and in vivo 
(49). VPA and SAHA treatment, in combination with 
all-trans retinoic acid (ATRA), restore E-cadherin, 
TSGs RARb2, P53, and P21CIP1 expression in human 
cervical cancer cells (50). It has been also reported 
that S-valproate reduces transcriptional suppressor 
of E-cadherin proteins vimentin and ZEB1 and 
increases E-cadherin protein expression in non-small 
cell lung cancer (51). Based on previous studies, VPA 
treatment increases the expression of E-cadherin in 
RM1 and PC3 cell lines, and might be useful to inhibit 
E-cadherin-mediated migration in prostate cancer 
cells (52, 53). 
The effects of VPA on cervical cancer cell lines 
have been also investigated before. VPA has shown a 
growth inhibitory effect on HeLa, SiHa, and CaSki 
cervical cancer cell lines (54, 55). VPA increases p53 
transcription and protects it from degradation by E6 
(54). Evaluating the effects of VPA on cervical cancer 
cell lines HeLa, SiHa, and CaSki and in vivo cancer 
models demonstrated increased p21 expression and 
histone H3 acetylation. Chronic treatment of VPA 
significantly decreased tumor growth and improved 
survival in tumor xenograft studies (56). Another 
study revealed that VPA treatment suppresses cell 
growth and induces cell cycle arrest in human 
cervical cancer HeLa cells, and also increases the 
tumor suppressor, Notch1 (57). 
According to our findings, E-cadherin 
augmentation in HPV positive cell lines, HeLa and 
TC-1, is higher than HPV negative cell lines, MKN45 
and HCT116. Previous studies have showed the effect 
of HPV E7 oncoprotein on E-cadherin expression, 
one study revealed that the expression of the HPV16 
E7 in MDCK cells reduces the expression of E-
cadherin (30), and suppression of HPV E7 using 
siRNA in HPV16 transformed human keratinocytes 
restores the E-cadherin expression in this cell (31). 
We studied the effects of VPA on HPV E7 expression 
in HeLa and TC1 cell lines; VPA significantly 
decreased HPV E7 mRNA level in both cell lines. This 
reduction of HPV E7 expression by VPA might lead to 
more augmentation of E-cadherin in HPV positive 
cell lines.  
 
Conclusion 
VPA increases E-cadherin expression in HPV 
positive cell lines and HPV negative cell lines; 
however, E-cadherin augmentation in HPV positive 
cell lines is higher than HPV negative cell lines. VPA 
decreases HPV E7 mRNA level in HeLa and TC-1 cell 
lines, which might lead to augmentation of                        
E-cadherin in HPV positive cell lines. VPA showed 
anticancer properties and could potentially be a 
promising candidate for further cervical cancer 
treatment. 
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